



ISSN: 0975-766X

CODEN: IJPTFI

Review Article

Available Online through

www.ijptonline.com

ROLE OF AUTOPHAGY ON CHEMOTHERAPY

Mandava Mahima Swaroopa¹, Sajja Sai Premika¹, Chinnam Sri Varsha¹, Pulimala Saranya¹

¹Working as Lecturers in KVSR Siddhartha College of Pharmacy

Email: mandavamahima12@gmail.com

Received on 27-02-2020

Accepted on: 29-03-2020

Abstract

Autophagy can help drugs drive malignancy cells into apoptosis, malignancy cells can capture autophagy to dodge the worry of hostile to disease medicates that are intended to execute them. This makes autophagy an alluring focus for hostile to disease treatments; blocking autophagy may make malignant growth cells unfit to defeat the worry of medicines, prompting their passing. Indeed, many clinical preliminaries are trying the capacity of autophagy-inhibitors alongside chemotherapy medications. Autophagy enlistment likewise diminishes mitochondrial mass by mitophagy (mitochondrial debasement via autophagy), and it has been accounted for this lessens the defenselessness of cells to mitochondrial apoptosis instigating stimuli. *vitro* and *in vivo* trial settings that treatment with Nutlin within the sight of bafilomycin A1 or chloroquine, known inhibitors of autophagy, brought about expanded dimensions of PUMA mRNA in a human colon malignancy cell line (HCT116).

KEYWORDS;

1. Unc-51-like kinase (ULK)
2. Autophagy-related-5 (Atg5)
3. 5'-AMP-actuated protein kinase (AMPK)
4. Demise related protein kinases (DAPk)
5. Inositol-trisphosphate (IP3)
6. Human colon malignancy cell line (HCT116)

Overall Review

Autophagy was portrayed very nearly 50 years back in mammalian cells¹. Autophagy can help drugs drive malignancy cells into apoptosis. An apoptotic reaction in tumors cells has been appeared to assume a noteworthy job in deciding the cytotoxicity in light of DNA harming specialists, for example, ionizing radiation and a few unique classes of chemotherapeutic drugs². Autophagy is engaged with numerous parts of human wellbeing and sickness, including malignant growth. Aggregating proof recommends that autophagy is a twofold edged sword in tumor beginning, working as both a tumor silencer and a defender of malignant growth cell survival³. Other than its job in homeostatic capacities, for example, protein and organelle turnover happening in basically all eukaryotic cells, autophagy is quickly upregulated in light of stresses like starvation, development factor withdrawal or high lively requirements⁴. autophagy goes about as a sort of cell reusing framework in which undesirable or old pieces of the cell are corrupted and reused to advance cell wellbeing. Lamentably, malignancy cells can capture autophagy to dodge the worry of hostile to disease medicates that are intended to execute them. This makes autophagy an alluring focus for hostile to disease treatments; blocking autophagy may make malignant growth cells unfit to defeat the worry of medicines, prompting their passing. Indeed, many clinical preliminaries are trying the capacity of autophagy-inhibitors alongside chemotherapy medications, radiation or focused on medicines to drive disease cells over the edge into a particular sort of cell demise known as apoptosis. Autophagy is a profoundly controlled procedure. The procedure begins with the initiation of an Unc-51-like kinase (ULK) complex made out of ULK1/2, Atg13, FIP200, and Atg1015. This complex is managed by mTOR which detects supplement levels in the earth. Under high-supplement conditions, mTOR phosphorylates ULK1/2 and afterward restrains autophagy; while mTOR separates from the ULK complex amid times of supplement hardship and actuates autophagy The initiation and gathering of the ULK complex outcome in the improvement of the segregation membranes⁶. Autophagy has a comparative system of balance: FOXO3a controls and is managed via autophagy. This implies when autophagy goes up, FOXO3a goes down, which thus acts to dial back autophagy. Furthermore, when autophagy goes down, FOXO3a goes up, which revives autophagy. By this component, autophagy stays moderately constant...even, at times, notwithstanding oncologists' endeavors to hose it with drugs.A direct connection among autophagy and

*Mandava Mahima Swaroopa*et al. /International Journal of Pharmacy & Technology*

disease was the disclosure that Beclin-1 could capacity as a tumor suppressor⁷. Autophagy enlistment likewise diminishes mitochondrial mass by mitophagy (mitochondrial debasement via autophagy), and it has been accounted for this lessens the defenselessness of cells to mitochondrial apoptosis instigating stimuli⁸. constraint of current treatment is that numerous malignant growths create protection from apoptosis, treatments focusing on elective cell passing pathways are appealing. Along these lines, it has been recommended that endeavors to build autophagy and in this way initiate autophagic cell demise when tumor cells are equipped for maintaining a strategic distance from apoptosis ought to be sought after. This is, obviously, something contrary to the methodology that has been proposed (i.e., that we should endeavor to hinder autophagy) so as to avoid autophagy-intervened obstruction against treatment. Along these lines, regardless of whether autophagy is a defensive system that diminishes tumor cell demise upon treatment, or on the off chance that it goes about as an apoptosis advancing component or as a cell passing instrument in essence is a significant issue that should be resolved. This inquiry is particularly squeezing seconds ago in light of the fact that both affirmed and test anticancer treatments incite the collection of autophagosomes in tumor cells and control of autophagy amid malignancy treatment is now being sought after. For instance, both rapamycin, an autophagy inducer that represses mTOR and chloroquine, an autophagy inhibitor that obstructs the autophagosome-lysosome combination step, are being utilized in blend with other chemotherapy in clinical preliminaries for various malignant growth types. Beneath we talk about some ongoing investigations utilizing autophagy control together with disease treatment, an outline of the techniques used to test autophagy

Apoptosis, a type of modified cell demise (type I), has been all around described. It includes the initiation of catabolic compounds – specifically proteases – in flagging falls, which prompts trademark changes, for example, adjusted atomic morphology including chromatin buildup and fracture, cell shrinkage, plasma layer blebbing, and apoptotic body formation⁹. Receptive oxygen species trigger apoptosis as well as invigorate the proteolytic action of Atg4 and afterward enact autophagy¹⁰. Atg5 (autophagy-related-5) additionally speaks to a point of crosstalk among autophagic and apoptotic pathways. Atg5 is required for autophagy. It conjugates to Atg12 and partners with separation films to shape autophagosomes¹¹. Autophagy is likewise upregulated when cells are getting ready to experience basic redesigning, for example, amid formative advances or to free

themselves of harming cytoplasmic parts, for instance, amid oxidative pressure, contamination, or protein total aggregation. Dietary status, hormonal variables, and different signs like temperature, oxygen focuses, and cell thickness are significant in the control of autophagy. The sub-atomic course that manages and executes autophagy has been the subject of later, exhaustive reviews¹². Autophagy can be pharmacologically instigated by restraining negative controllers, for example, TOR with rapamycin¹³. One of the key controllers of autophagy is the objective of rapamycin, TOR kinase, which is the major inhibitory sign that closes off autophagy within the sight of development factors and rich supplements. The class I PI3K/Akt flagging particles interface receptor tyrosine kinases to TOR actuation and in this way quell autophagy because of insulin-like and other development factor signals¹⁴. A portion of the other administrative particles that control autophagy incorporate 5'-AMP-actuated protein kinase (AMPK), which reacts to low vitality; the eukaryotic commencement factor 2 α (eIF2 α), which reacts to supplement starvation, twofold stranded RNA, and endoplasmic reticulum (ER) stress; BH3-just proteins that contain a Bcl-2 homology-3 (BH3) area and upset Bcl-2/Bcl-XL hindrance of the Beclin 1/class III PI3K complex; the tumor silencer protein, p53; demise related protein kinases (DAPk); the ER-layer related protein, Ire-1; the pressure enacted kinase, c-Jun-N-terminal kinase; the inositol-trisphosphate (IP3) receptor (IP3R); GTPases; Erk1/2; ceramide; and calcium¹⁵. Autophagy can be pharmacologically hindered by focusing on the class III PI3K associated with autophagosome development with 3-methyladenine or by focusing on the combination of autophagosomes with lysosomes, utilizing inhibitors of the lysosomal proton siphon, for example, bafilomycin A1 or lysosomotropicalkalines, for example, chloroquine and 3-hydroxychloroquine¹⁶. To additionally investigate the impact of autophagy balance on the p53 transcriptional program that is known to control PUMA quality articulation, the creators utilized Nutlin, an enemy of malignant growth medicate that builds the dimensions of p53 by hindering the movement of the ubiquitin E3 ligase MDM2, which is in charge of focusing on p53 for proteasomal degradation. They appeared in vitro and in vivo trial settings that treatment with Nutlin within the sight of bafilomycin A1 or chloroquine, known inhibitors of autophagy, brought about expanded dimensions of PUMA mRNA in a human colon malignancy cell line (HCT116). Interestingly, this blend was capable, through PUMA initiation by means of both p53 and FOX3a, to switch the Nutlin treatment impact from cell development

*Mandava Mahima Swaroopa*et al. /International Journal of Pharmacy & Technology*
capture to apoptosis. Reliable with this, xenografted HCT116 tumors were receptive to the blend of Nutlin and chloroquine, though HCT116 cells in which PUMA does not have the FHRE were not receptive to the drugs. Muscle ailments in which autophagy may advance the freedom of malady causing proteins incorporate sporadic consideration body myositis, appendage support strong dystrophy type 2B, and Miyoshi myopathy. In sporadic incorporation body myositis, the most well-known obtained muscle malady in patients over 50 years old, overexpression of amyloid forerunner protein (APP) and collection of its proteolytic part β -amyloid in vacuolated cells is believed to be a focal pathogenetic mechanism¹⁷. faulty autophagy (because of hindered autophagosome-lysosome combination) may assume a job in generally uncommon types of acquired infections of the heart (e.g., Danon sickness, Pompe malady). Of more noteworthy restorative essentialness is the likelihood that autophagy may comprise a significant physiological or pathophysiological reaction to cardiovascular anxieties, for example, ischemia or weight over-burden, which are regularly experienced in patients with coronary corridor infection, hypertension, aortic valvular ailment, and congestive heart failure. The aggregation of autophagosomes has been noted in cardiovascular biopsy tissues of patients with these disarranges, rat models of these cardiovascular maladies, and secluded focused on cardiomyocytes¹⁸. In the previous decade, a few hereditary connections have risen between autophagy deformities and malignant growth, giving expanding backing to the idea that autophagy is a true blue tumor silencer pathway¹⁹. The guideline of autophagy covers intimately with flagging pathways that control tumorigenesis. A few tumor silencer qualities associated with the upstream hindrance of TOR signaling, including PTEN, TSC1, and TSC2, invigorate autophagy furthermore, on the other hand, TOR-enacting oncogene items, for example, class I PI3K and Akt repress autophagy (Table 2). P53, the most usually changed tumor silencer quality in human diseases, decidedly controls autophagy in DNA-harmed cells, maybe through AMPK enactment of the TSC1/TSC2 complex and subs.

Conclusion

Autophagy is engaged with numerous parts of human wellbeing and sickness, including malignant growth. Aggregating proof recommends that autophagy is a twofold edged sword in tumor beginning, working as both a tumor silencer and a defender of malignant growth cell survival. Nutlin treatment impact from cell development

*Mandava Mahima Swaroopa*et al. /International Journal of Pharmacy & Technology*
capture to apoptosis. Reliable with this, xenografted HCT116 tumors were receptive to the blend of Nutlin and chloroquine, though HCT116 cells in which PUMA does not have the FHRE were not receptive to the drugs. . Autophagy can be pharmacologically hindered by focusing on the class III PI3K associated with autophagosome development with 3-methyladenine or by focusing on the combination of autophagosomes with lysosomes, utilizing inhibitors of the lysosomal proton siphon, for example, bafilomycin A1 or lysosomotropicalkalines, for example, chloroquine and 3-hydroxychloroquine.

References

1. Participation of lysosomes in cellular autophagy induced in rat liver by glucagon.*Deter RL, Baudhuin P, De Duve C J Cell Biol. 1967 Nov; 35(2):C11-6.*[\[PubMed\]](#) [\[Ref list\]](#)
2. Brown J. M., Wouters B. G. (1999). Apoptosis, p53, and tumor cell sensitivity to anticancer agents. *Cancer Res. 59, 1391–1399* [\[PubMed\]](#) [\[Google Scholar\]](#)
3. Shintani T., Klionsky D. J. (2004). Autophagy in health and disease: a double-edged sword. *Science*306, 990–995. [10.1126/science.1099993](https://doi.org/10.1126/science.1099993) [\[PMC free article\]](#) [\[PubMed\]](#) [\[CrossRef\]](#) [\[Google Scholar\]](#)
4. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. *Cell. 2008;132:27–42.*[\[PMC free article\]](#) [\[PubMed\]](#) [\[Google Scholar\]](#)
5. Regulation mechanisms and signaling pathways of autophagy.*He C, Klionsky DJAnnu Rev Genet. 2009; 43():67-93.*
[\[PubMed\]](#) [\[Ref list\]](#)
6. Mammalian autophagy: core molecular machinery and signaling regulation.*Yang Z, Klionsky DJ Curr Opin Cell Biol. 2010 Apr; 22(2):124-31.*[\[PubMed\]](#) [\[Ref list\]](#)
7. Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H, et al. Induction of autophagy and inhibition of tumorigenesis by beclin 1. *Nature. 1999;402:672–676.* [\[PubMed\]](#) [\[Google Scholar\]](#)
8. Rapamycin pre-treatment protects against apoptosis. *Ravikumar B, Berger Z, Vacher C, O’Kane CJ, Rubinsztein DC Hum Mol Genet. 2006 Apr 1; 15(7):1209-16.* [\[PubMed\]](#) [\[Ref list\]](#)

9. Programmed cell death: apoptosis and oncogenesis. *Williams GT Cell.* 1991 Jun 28; 65(7):1097-8. [PubMed]

[Ref list]

10. Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4. *Scherz-Shouval R, Shvets E, Fass E, Shorer H, Gil L, Elazar Z EMBO J.* 2007 Apr 4; 26(7):1749-60. [PubMed]

[Ref list]

11. A new protein conjugation system in human. The counterpart of the yeast Apg12p conjugation system essential for autophagy. *Mizushima N, Sugita H, Yoshimori T, Ohsumi Y J Biol Chem.* 1998 Dec 18; 273(51):33889-92. [PubMed] [Ref list]

12. Klionsky, D.J. (2007). Autophagy: from phenomenology to molecular understanding in less than a decade. *Nat. Rev. Mol. Cell Biol.* 8, 931–937

13. Rubinsztein, D.C., Gestwicki, J.E., Murphy, L.O., and Klionsky, D.J. (2007). Potential therapeutic applications of autophagy. *Nat. Rev. Drug Discov.* 6, 304–312.

14. Lum, J.J., Bauer, D.E., Kong, M., Harris, M.H., Li, C., Lindsten, T., and Thompson, C.B. (2005). Growth factor regulation of autophagy and cell survival in the absence of apoptosis. *Cell* 120, 237–248

15. Criollo, A., Maiuri, M.C., Tasdemir, E., Vitale, I., Fiebig, A.A., Andrews, D., Molgo, J., Diaz, J., Lavandro, S., Harper, F., et al. (2007). Regulation of autophagy by the inositol trisphosphate receptor. *Cell Death Differ.* 14, 1029–1039

16. Rubinsztein, D.C., Gestwicki, J.E., Murphy, L.O., and Klionsky, D.J. (2007). Potential therapeutic applications of autophagy. *Nat. Rev. Drug Discov.* 6, 304–312.

17. Askanas, V., and Engel, W.K. (2006). Inclusion-body myositis: a myodegenerative conformational disorder associated with A β , protein misfolding, and proteasome inhibition. *Neurology* 66, S39–S48.

18. Terman, A., and Brunk, U.T. (2005). Autophagy in cardiac myocyte homeostasis, aging, and pathology. *Cardiovasc. Res.* 68, 355–365.

19. Levine, B., and Deretic, V. (2007). Unveiling the roles of autophagy in innate and adaptive immunity. *Nat. Rev. Immunol.* 7, 767–777.
- 20 Crichton, D., Wilkinson, S., O’Prey, J., Syed, N., Smith, P., Harrison, P.R., Gasco, M., Garrone, O., Crook, T., and Ryan, K.M. (2006). DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. *Cell* 126, 121–134.
21. Abedin MJ, Wang D, McDonnell MA, Lehmann U, Kelekar A. Autophagy delays apoptotic death in breast cancer cells following DNA damage. *Cell Death Differ.* 2007;14:500–510. [[PubMed](#)] [[Google Scholar](#)] [[Ref list](#)]
22. Li J, Hou N, Faried A, Tsutsumi S, Kuwano H. Inhibition of autophagy augments 5-fluorouracil chemotherapy in human colon cancer in vitro and in vivo model. *Eur J Cancer.* 46:1900–1909. [[PubMed](#)] [[Google Scholar](#)] [[Ref list](#)]
23. Amaravadi RK, Yu D, Lum JJ, Bui T, Christophorou MA, Evan GI, et al. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. *J Clin Invest.* 2007;117:326–336. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)] [[Ref list](#)]

Corresponding Author:

Mandava Mahima Swaroopa*,

Email: mandavamahima12@gmail.com